Viral load peaks in early stages of COVID-19, study shows

In a retrospective study, investigators from New York University Langone Health found that the quantity of SARS-CoV-2 (viral load) collected from patients in the emergency department is significantly higher in patients with fewer or milder symptoms who did not require hospitalization--the opposite of what might be expected.

Reporting in The American Journal of Pathology, published by Elsevier, they also found that a patient's history of cancer and cardiovascular disease is associated with higher viral loads even after adjusting for age.

The study was designed to determine possible associations between the viral load measured in patients positive for SARS-CoV-2 and their clinical parameters including severity of symptoms, hospital admission vs direct discharge, length of hospitalization, admission to the intensive care unit, length of need for oxygen support, and overall survival.

It appears that the viral load peaks in the early stages of the disease. Although it is not associated with the duration of symptoms, their severity or outcome, it appears that the viral load is an important epidemiological surrogate marker of infectivity in mildly symptomatic and asymptomatic non-hospitalized patients."

Paolo Cotzia, MD, Assistant Director, Center for Biospecimen Research and Development, NYU Langone Health

Cotzia is also a co-led investigator and Assitant Professor of the department of pathology.

"Whether the viral load in these patients stays the same or changes in later stages of the disease remains to be investigated and could provide further insights on the dynamics of viral replication."

Two hundred and five patients who visited the emergency department at a New York City tertiary care center with confirmed COVID-19 were included in the study. Nasopharyngeal samples were taken at the time of diagnosis. One hundred and sixty-five patients were discharged from the emergency department, and 40 patients were hospitalized.

Non-hospitalized patients were younger overall, and other characteristics were similar across the group. The median duration from symptom onset to sample collection for the hospitalized group was five days compared with three days for the discharged patients.

Investigators found that the initial viral load was significantly lower in patients who required hospitalization compared to those who were discharged.

The association remained significant even after adjustment for age, sex, race, body mass index, and other existing medical conditions. They also found that a higher viral load was associated with shorter duration of symptoms in all patients and was not associated with disease severity.

Co-lead investigator George Jour, MD, Assistant Professor, Department of Pathology and Department of Dermatology, Associate Director Molecular Pathology, NYU Langone Health, New York City, NY, USA, observed, "Another important finding of our study is that the initial nasopharyngeal viral load reflects the time from onset of symptoms and duration of symptoms.

We found that higher viral loads are seen in mild rather than in severe disease because they appear to reflect the time lapsed from the onset of infection. Furthermore, higher viral loads correlate with the presence of cancer or cardiovascular diseases."

Although diagnostic viral load seems to have no prognostic utility for predicting outcomes from COVID-19, the investigators say it may be an important surrogate marker in mildly symptomatic, non-hospitalized patients.

Their results support the concept that such patients may represent important sources of the virus. "Our study should increase awareness and should prompt the adherence to strict recommendation of social distancing and mask usage to avoid transmission," the investigators concluded.

Source:
Journal reference:

Argyropoulos, K. V., et al. (2020) Association of Initial Viral Load in SARS-CoV-2 Patients With Outcome and Symptoms. American Journal of Pathology. doi.org/10.1016/j.ajpath.2020.07.001.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
A revolutionary antibody approach to fight cancer by restoring cellular fitness